Rocket


News + Filings
Key Docs
Charts
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Amryt Pharma Plc (AMYT) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/06/2021 GN Amryt Announces the Appointment of Sheila Frame as President Americas
03/31/2021 GN Amryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
03/29/2021 GN Amryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
03/23/2021 GN Amryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
03/22/2021 GN Amryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
03/15/2021 GN Director/PDMR Shareholding
03/12/2021 GN Exercise of Options and Total Voting Rights
03/11/2021 GN Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
03/08/2021 GN Director/PDMR Shareholding
03/08/2021 GN Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada
02/24/2021 GN Amryt to Announce Q4 and FY 2020 Results on Thursday March 4, 2021
02/04/2021 GN Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel
01/20/2021 GN Amryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
12/23/2020 GN Amryt Granted Orphan Drug Designation by the FDA for AP103
12/17/2020 GN Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
12/11/2020 GN Holding(s) in Company
12/09/2020 GN Holding(s) in Company
12/09/2020 GN Amryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil
12/08/2020 GN Amryt Announces $40m Private Placement with Leading Biotech Investors
10/19/2020 GN Amryt and Swixx Sign Distribution Deal for Lojuxta
10/14/2020 GN Notice of Results
10/12/2020 GN Holding(s) in Company
10/09/2020 GN Virtual Analyst & Investor Event - Tuesday November 3, 2020
10/08/2020 GN AMRYT TO PRESENT EASE TRIAL DATA BY LATE-BREAKING PRESENTATION AT EADV ON OCTOBER 31, 2020
10/01/2020 GN Exercise of Options and Total Voting Rights
09/30/2020 GN Holding(s) in Company
09/23/2020 GN AMRYT SUPPORTS GLOBAL FH AWARENESS DAY – SEPTEMBER 24, 2020
09/21/2020 GN Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
09/15/2020 GN AMRYT RECEIVES POSITIVE OPINION FROM EMA ON ORPHAN DRUG DESIGNATION FOR AP103
08/11/2020 GN AMRYT PHARMA NOTIFICATION OF CANCELLATION OF ADMISSION TO EURONEXT GROWTH
08/06/2020 GN AMRYT ANNOUNCES Q2 2020 RESULTS AND ISSUES POSITIVE REVENUE GUIDANCE FOR FY 2020
07/29/2020 GN AMRYT TO HOST KEY OPINION LEADER CALL ON EPIDERMOLYSIS BULLOSA DISEASE LANDSCAPE
07/20/2020 GN AMRYT TO ANNOUNCE Q2 RESULTS ON AUGUST 6, 2020
07/08/2020 GN AMRYT LISTED ON NASDAQ AND CEO TO RING NASDAQ CLOSING BELL
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy